Table 4.
Cost and proportion of patients for empiric use of Voriconazole vs. LAmB
| Outcome |
Voriconazole |
LAmB |
||||
|---|---|---|---|---|---|---|
| Proportion (%) | Cost (TL) | Proportionate cost (TL)* | Proportion (%) | Cost (TL) | Proportionate cost (TL)* | |
|
No baseline fungal infection | ||||||
|
Successful treatment |
24.58 |
11,551 |
2,839 |
29.62 |
19,492 |
5,774 |
|
Mortality |
7.95 |
11,551 |
919 |
5.92 |
19,492 |
1,155 |
|
Breakthrough fungal infection |
1.93 |
29,777 |
574 |
4.98 |
31,593 |
1,572 |
|
Premature discontinuation |
9.88 |
30,179 |
2,982 |
6.64 |
29,784 |
1,976 |
|
Persistent fever |
52.53 |
30,350 |
15,943 |
51.42 |
30,075 |
15,465 |
|
Baseline fungal infection | ||||||
|
Successful treatment |
1.45 |
11,551 |
167 |
0.95 |
25,832 |
245 |
|
Mortality |
0.00 |
0 |
0 |
0.00 |
0 |
0 |
|
Persistent baseline fungal infection |
1.69 |
24,400 |
412 |
0.47 |
36,207 |
172 |
| Total | 100.00 | -- | 23,835 | 100.00 | -- | 26,358 |
*Individual costs may not sum to actual total as all figures are rounded to the nearest full Turkish Lira (TL).